Comparison
Survodutide vs. Thymosin Alpha-1
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Healing
CAS no.
2179963-22-7
62304-98-7
Molecular weight
4727 g/mol
3108.32 g/mol
Half-life
168 h
2 h
Sequence
modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteAc-SDAAVDTSSEITTKDLKEKKEVVEEAENMechanism of action
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Thymosin Alpha-1
Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
2
2
of which in humans
2
2
Effects recorded
3
3
Open conflicts
0
1
Documented adverse events
2
1